# A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension

> **NCT04133311** · PHASE3 · COMPLETED · sponsor: **Santen SAS** · enrollment: 386 (actual)

## Conditions studied

- Open-Angle Glaucoma or Ocular Hypertension
- Ocular Surface Disease

## Interventions

- **DRUG:** DE-130A
- **DRUG:** Xalatan®
- **DRUG:** DE-130A/DE-130A
- **DRUG:** Xalatan®/DE-130A

## Key facts

- **NCT ID:** NCT04133311
- **Lead sponsor:** Santen SAS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-10
- **Primary completion:** 2022-02-03
- **Final completion:** 2022-10-26
- **Target enrollment:** 386 (ACTUAL)
- **Last updated:** 2024-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04133311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04133311, "A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04133311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*